BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.31B +99.2% |
| Revenue (ttm) | 162.56M +27.1% |
| Net Income | 20.69M +316.5% |
| EPS | 0.42 +213.1% |
| Shares Out | 39.22M |
| PE Ratio | 79.14 |
| Forward PE | 54.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,552 |
| Average Volume | 150,572 |
| Open | 3,400.00 |
| Previous Close | 3,410.00 |
| Day's Range | 3,313.00 - 3,425.00 |
| 52-Week Range | 1,444.00 - 3,999.00 |
| Beta | 0.32 |
| RSI | 41.86 |
| Earnings Date | Mar 18, 2026 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
News
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adul...
BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed on...
BrainsWay (BWAY) Gains Expanded Insurance Coverage for Depression Treatment
BrainsWay (BWAY) Gains Expanded Insurance Coverage for Depression Treatment
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.
BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™
Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older Optum B...
Brainsway Ltd Analyst and Investor Day Transcript
Brainsway Ltd Analyst and Investor Day Transcript
Are Options Traders Betting on a Big Move in BrainsWay Stock?
Investors need to pay close attention to BrainsWay stock based on the movements in the options market lately.
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025
BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment
BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment
BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder
Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings Multicenter, randomized, controlled study will eva...
BrainsWay: High Growth Set To Persist
BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News
BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News
BrainsWay (BWAY) Gains FDA Nod for Expanded Use of Deep TMS in Adolescents
BrainsWay (BWAY) Gains FDA Nod for Expanded Use of Deep TMS in Adolescents
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 1...
BrainsWay Ltd (BWAY) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
BrainsWay Ltd (BWAY) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives
Q3 2025 Brainsway Ltd Earnings Call Transcript
Q3 2025 Brainsway Ltd Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript
BrainsWay Ltd. ( BWAY) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants B...
BrainsWay (BWAY) Q3 Revenue Surpasses Expectations, Raises 2025 Guidance
BrainsWay (BWAY) Q3 Revenue Surpasses Expectations, Raises 2025 Guidance
BrainsWay GAAP EPS of $0.04 in-line, revenue of $13.51M beats by $0.47M
BrainsWay reports strong Q3 results with revenue up 28.7% and raises FY25 guidance.
BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights
R evenue increase d 29% to $ 13.5 million in Q3 2025 as compared with Q 3 202 4
Earnings Scheduled For November 11, 2025
Companies Reporting Before The Bell • Gogoro (NASDAQ: GGR) is estimated to report earnings for its third quarter. • ChipMOS TECHNOLOGIES (NASDAQ: IMOS) is estimated to report earnings for its third ...
BrainsWay Q3 2025 Earnings Preview
Insights into BrainsWay's Upcoming Earnings
BrainsWay (NASDAQ: BWAY) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-11. Here's a quick overview of what investors should know before the release. Analysts are estimating tha...